Alzheimer-kór: vizsgálatok itt: Dél-Korea

In Dél-Korea 31 Also abroad 815

31 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

2/3. fázisTaking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Incheon, Seoul
Életkor
55 év to 95 év
People
1074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
3. fázisCsak meghívásos
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Incheon, Seoul
Életkor
55 év to 95 év
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
2. fázisTaking people
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Where
Gangnam-gu, Incheon, Namdong-gu, Seoul
Életkor
55 év to 85 év
People
350 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07589595
3. fázisTaking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Deagu, Incheon, Seoul
Életkor
55 év to 90 év
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
3. fázisTaking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Ansan-si, Gangwon-do, Seoul, Yeongdeungpo-gu, Yongin-si
Életkor
55 év to 90 év
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Gwangju, Seongnam, Seoul
Életkor
60 év to 85 év
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
2. fázisTaking people
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Where
Seoul
Életkor
50 év to 85 év
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00
3. fázisTaking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon
Életkor
50 év to 90 év
People
80 000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
No phaseTaking people
Clinical Cohort of Memory Disorders
Where
Seoul
Életkor
19 év and over
People
1550
Run by
Yonsei University
See details and how to joinNCT07880275
3. fázisTaking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Ansan-si, Buk-gu, Gangwon-do, Incheon, Seongnam-si, Seoul, Yeongdeungpo-gu, Yongin-si
Életkor
55 év to 90 év
People
1000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
3. fázisTaking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Buk-gu, Busan, Incheon, Seongnam-si, Seoul
Életkor
55 év to 90 év
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
3. fázisTaking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Deagu, Incheon, Seoul
Életkor
55 év to 90 év
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
No phaseTaking people
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
Where
Seoul
Életkor
50 év to 85 év
People
10
Run by
Neumous Inc.
See details and how to joinNCT07869238
No phaseTaking people
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
Where
Cheonan
Életkor
60 év to 85 év
People
30
Run by
ReadyCure Inc.
See details and how to joinNCT07863011
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
Seoul
Életkor
18 év and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
2. fázisTaking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Daegu, Incheon
Életkor
55 év to 90 év
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
No phaseCsak meghívásos
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Where
Seoul
Életkor
60 év and over
People
60
Run by
NVP Healthcare
See details and how to joinNCT06761066
3. fázisTaking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Where
Junggu, Pusan, Seoul
Életkor
55 év to 90 év
People
410 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363
No phaseTaking people
Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
Where
Cheonan, Hwaseong-si, Incheon, Seongnam-si, Seoul, Suwon
Életkor
55 év to 90 év
People
138
Run by
Deepsonbio
See details and how to joinNCT07239310
2/3. fázisTaking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Seoul
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
2/3. fázisTaking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Seoul
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
2. fázisTaking people
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
Where
Guri-si, Gwangju, Incheon, Seoul, Suwon
Életkor
50 év to 85 év
People
114
Run by
NeuroBiogen Co., Ltd
See details and how to joinNCT07027072
No phaseTaking people
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
Where
Busan, Daegu, Daejeon, Gwangju, Gwangmyeong, Gyeonggi-do, Incheon, Jeonju, Seoul
Életkor
60 év to 85 év
People
180
Run by
Advanced Technology & Communications
See details and how to joinNCT06088121
No phaseNot yet taking people in Dél-Korea
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
Where
Seoul
Életkor
50 év to 90 év
People
60
Run by
Yonsei University
See details and how to joinNCT07544953
No phaseTaking people
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Where
Gyeonggi-do, Seoul
Életkor
55 év to 85 év
People
60
Run by
CKD Bio Corporation
See details and how to joinNCT07496021